Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

201792 citationsJournal Articlehybrid Open Access

Authors

Gabe S. Sonke · The Netherlands Cancer Institute

Lowell L. Hart · Florida Cancer Specialists & Research Institute

Mario Campone · Institut de Cancérologie de l'Ouest

Frans Erdkamp · Zuyderland Medisch Centrum

Wolfgang Janni · University Hospital Ulm

Sunil Verma · Occupational Cancer Research Centre

Cristian Villanueva

Abstract

Addition of ribociclib to letrozole is a valid therapeutic option for elderly patients with HR+, HER2- advanced breast cancer in the first-line setting.

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Breast Cancer Research and Treatment

Volume 167, Issue 3, pp. 659-669

DOI: 10.1007/s10549-017-4523-y

Field-Weighted Citation Impact: 7.58